Clinical trials
Ovarian cancer clinical trials
Cancer that starts in the ovaries, often found at a later stage. We’re tracking 599 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07435701RecruitingPhase 1/Phase 2
Cell injection into belly for advanced ovarian cancer with fluid buildup
This trial tests a new type of therapy where special cells (called SK-NK cells) are injected directly into the belly to treat fluid buildup (ascites) caused by advanced ovarian cancer. It is for patients whose cancer has not responded to at least two prior treatments and who have no other standard options left.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07667751RecruitingPhase 2
Study of Ipalotinib with Sunitinib and Olaparib before surgery for advanced ovarian cancer
This trial tests a combination of three drugs (Ipalotinib, Sunitinib, and Olaparib) given before surgery to shrink tumors in people with a specific type of advanced ovarian cancer that has a genetic marker called HRD-positive. The goal is to see if this treatment helps make surgery more effective.
HefeiAges 18–75 - NCT07540403Recruiting
Study of ovarian cancer outcomes in treatment-resistant cases
This research study follows patients with epithelial ovarian cancer that has returned or worsened quickly after treatment (within 6 months). The goal is to understand survival patterns and outcomes in these difficult-to-treat cases to potentially improve future care.
RomeAges 18 years+ - NCT07470853RecruitingPhase 1
Study of HWK-016 for advanced ovarian or endometrial cancer
This trial tests a new drug called HWK-016, which is designed to target and deliver medicine directly to cancer cells that have a specific marker (MUC16). It is for people with advanced ovarian or endometrial cancer to see if it can shrink tumors or slow their growth.
Little Rock, ArkansasAges 18 years+ - NCT06331130Recruiting
Mesenteric involvement in ovarian cancer trial
This study is looking at how ovarian cancer affects the mesentery (the tissue that holds your intestines in place) in women with advanced ovarian cancer. It helps doctors understand the disease better and may lead to improved treatments.
RomaAges 18 years+ - NCT07220512Recruiting
Exercise help for ovarian, fallopian, or endometrial cancer
This trial tests a special exercise program during chemotherapy before surgery. It may help patients with certain gynecologic cancers get stronger and better prepared for treatment.
Winston-Salem, North CarolinaAges 55 years+ - NCT07156253RecruitingPhase 1
Study of SYN818 with olaparib for advanced solid tumors
This trial is testing a new drug, SYN818, combined with olaparib for people with advanced solid tumors that have certain genetic changes (BRCA mutations or related DNA repair problems). It may be an option if you have ovarian or HER2-negative breast cancer and other treatments are no longer working.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05518253RecruitingPhase 1
CAR-T treatment for CD70-positive advanced solid tumors
This trial tests a lab-made immune therapy (CAR-T) that targets a protein called CD70 found on some advanced cancers. It’s designed for people whose solid tumors have spread and no standard treatments have worked or weren’t tolerated.
Hangzhou, ZhejiangAges 18 years+ - NCT06963268RecruitingPhase 3
Testing sentinel lymph node surgery for early ovarian cancer
This study tests a way to check for cancer spread in the lymph nodes of the pelvis during surgery for early-stage ovarian cancer. It uses a special dye and tracer to find the first lymph node that drains from the tumor.
Valencia, ValenciaAges 18 years+ - NCT06799637RecruitingPhase 1/Phase 2
Study of XNW28012 for advanced solid tumors
This trial tests a new drug called XNW28012 for people with advanced solid tumors that have not responded to or caused side effects from standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Hefei, AnhuiAges 18 years+ - NCT06646627RecruitingPhase 1
B7-H3 car t cells for platinum-resistant ovarian cancer
This trial tests a new treatment where your own immune cells are modified to attack ovarian cancer cells that have stopped responding to platinum chemotherapy. It's for people with recurrent ovarian cancer that hasn't gotten better with standard treatments.
Palo Alto, CaliforniaAges 18 years+ - NCT03419689Recruiting
Study checks blood and tumor markers in advanced ovarian cancer
This study looks at “biomarkers,” meaning measurable signals in blood and tumor tissue, in people with advanced ovarian-type cancers. The goal is to understand these markers and how they relate to the cancer, which may help guide future care.
Barrie, OntarioAges 18 years+ - NCT07546500RecruitingPhase 3
Azenosertib versus chemotherapy for advanced ovarian cancer
This trial tests a new drug called azenosertib against standard chemotherapy for ovarian, fallopian tube, or peritoneal cancer that has come back after platinum-based treatment. The drug targets a specific protein (cyclin E1) found in some tumors and may help stop cancer cells from dividing.
Phoenix, ArizonaAges 18 years+ - NCT07772869Recruiting
Uterine washing test to detect ovarian cancer risk
This study is testing a new way to find ovarian cancer early. It uses a gentle washing of the uterus (like a Pap test) to collect cells and look for signs of cancer in women who are at high risk because of a BRCA gene mutation. The goal is to see if this method can detect cancer before it spreads, which might help save more lives.
Seattle, WashingtonAges 18 years+ - NCT06420973RecruitingPhase 2
Testing RC48 for ovarian cancer returning after platinum treatment
This trial tests a new drug, RC48, for people with ovarian cancer that came back after responding well to platinum chemotherapy. RC48 targets the HER2 protein on cancer cells, which may stop the tumor from growing. Researchers want to see if it's safe and works better than current options.
Beijing, Beijing MunicipalityAges 18–75 - NCT06522828RecruitingPhase 2
Study of SSGJ-707 for advanced gynecologic cancers
This trial tests a new drug called SSGJ-707 for people with advanced endometrial cancer or ovarian cancer that no longer responds to platinum-based chemotherapy. The goal is to see if it can help shrink or slow down the cancer.
ChongqingAges 18–75 - NCT05877599RecruitingPhase 1
Study of a new treatment for advanced cancers with a specific gene change
This trial tests a new type of therapy (NT-175) for people with certain advanced cancers that have a specific genetic change. It might help if your tumor has the TP53 R175H mutation and you have the HLA-A*02:01 immune marker.
Gilbert, ArizonaAges 18 years+ - NCT06553612Recruiting
Supportive care planning after gynecological cancer treatment
This study compares a special day-hospital visit focused on supportive care needs to standard follow-up for people who have finished initial treatment for ovarian or endometrial cancer. The goal is to see if the special visit helps more people get the supportive care they need.
BesançonAges 18 years+ - NCT06792552RecruitingPhase 1
Study of SIM0505 for advanced solid tumors
This trial tests a new drug called SIM0505 for people with advanced solid tumors that have not responded to standard treatments. The study looks at different cancer types, including ovarian cancer, kidney cancer, uterine cancer, and lung cancer, to see if SIM0505 can help shrink tumors or slow their growth.
Orlando, FloridaAges 18 years+ - NCT05287451Recruiting
Tube removal now, ovaries later for high cancer-risk women
This study looks at the safety of removing your fallopian tubes first (RRS) and delaying ovary removal (oophorectomy) to lower cancer risk. It focuses on women who carry certain inherited gene changes, and may help avoid earlier menopause for some people.
Chicago, IllinoisAges 18 years+ - NCT07286266RecruitingPhase 3
Testing a new drug for platinum-resistant ovarian cancer
This phase 3 trial tests a new drug, mocertatug rezetecan, against standard treatments for ovarian cancer that no longer responds to platinum chemo. It's for people who have had 1 to 4 prior therapies and may offer a new option if you haven't tried all standard treatments yet.
Randwick, New South WalesAges 18 years+ - NCT07684612RecruitingPhase 3
New drug combo for recurrent ovarian cancer
This trial tests a new drug called mocertatug rezetecan combined with bevacizumab against standard platinum chemo plus bevacizumab. It's for women with ovarian cancer that came back after treatment and is still sensitive to platinum drugs.
Newcastle, New South WalesAges 18 years+ - NCT05601700RecruitingPhase 3
Letrozole for low-grade ovarian cancer that uses hormones
This study tests whether letrozole, a hormone-blocking medicine, can help people with newly diagnosed low-grade serous ovarian cancer that has hormone receptor proteins (ER and/or PgR) after surgery. It compares outcomes to see if blocking estrogen can slow the cancer’s return or progression.
Arezzo, ARAges 18 years+ - NCT07213193Recruiting
a study about ovarian cancer surgery and bowel involvement in women like you who are taking a pill or something? actually, it's about whether to use a vaginal or something? wait, let's read the title. it's about a no-basic? wait. the title is
This study explores an alternative method to the previous approach of whether to bypass or not? or wait... it's about the use of something? wait... the title is... wait? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? title? you get the idea? ?title? ?title? ?title? ?title? ?title? ?title? ?title? ?title? ?title? ?title? ?title? ?title? ?title? ?title? ?title? ?title? ?title? ?title? ?title? ?title? ?title? ?title? ?until? ?title? ?title? ?title? ?title? ?title? flask? ?title? ?title? ?title? ?title? ?title? ?title? ?title? ?title? ?title? ?title? ?title? ? what? ?title? ?title? ?title? ?title? ?title? ?title? ?title? ? ???????????????
RomaAges 18 years+
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for ovarian cancer?
- Yes. Clin2 currently lists 599 recruiting ovarian cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a ovarian cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a ovarian cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.